MCID: LSH001
MIFTS: 72

Leishmaniasis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Leishmaniasis

MalaCards integrated aliases for Leishmaniasis:

Name: Leishmaniasis 12 77 54 56 44 45 15 17 74 3
Post-Kala-Azar Dermal Leishmaniasis 12 74
Kala-Azar 54 3
Post-Kala-Azar Dermal Infectious Disease by Leishmaniasis 12
Post Kala-Azar Dermal Leishmaniasis 12
Leishmaniasis, Cutaneous 74
Cutaneous Leishmaniasis 54
Leishmaniasis, Visceral 74
Visceral Leishmaniasis 54

Classifications:



Summaries for Leishmaniasis

MedlinePlus : 44 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver, and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Leishmaniasis is found in parts of about 88 countries. Most of these countries are in the tropics and subtropics. It is possible but very unlikely that you would get this disease in the United States. But you should be aware of it if you are traveling to the Middle East or parts of Central America, South America, Asia, Africa or southern Europe. Treatment is with medicines that contain antimony, a type of metal, or with strong antibiotics. The best way to prevent the disease is to protect yourself from sand fly bites: Stay indoors from dusk to dawn, when sand flies are the most active Wear long pants and long-sleeved shirts when outside Use insect repellent and bed nets as needed Centers for Disease Control and Prevention

MalaCards based summary : Leishmaniasis, also known as post-kala-azar dermal leishmaniasis, is related to visceral leishmaniasis and cutaneous leishmaniasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Leishmaniasis is RN7SL1 (RNA Component Of Signal Recognition Particle 7SL1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Amphotericin B and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and t cells, and related phenotypes are splenomegaly and hepatomegaly

Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by protozoan parasite of the genus Leishmania, which is transmitted by the bite of sand fly (subfamily Phlebotominae).

NIH Rare Diseases : 54 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Visceral disease can be deadly without proper treatment. Leishmaniasis is found in parts of the Middle East, Central America, South American, Asia, Africa, and southern Europe. Most of these countries are in the tropics and subtropics. It is possible but very unlikely to get this disease in the United States.

CDC : 3 Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a neglected tropical disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

Wikipedia : 77 Leishmaniasis is a disease caused by parasites of the Leishmania type. It is spread by the bite of... more...

Related Diseases for Leishmaniasis

Diseases related to Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 513)
# Related Disease Score Top Affiliating Genes
1 visceral leishmaniasis 34.6 IFNG IL10 IL4 NOS2 SLC11A1 TLR2
2 cutaneous leishmaniasis 34.1 IFNG IL10 IL13 IL4 IL5 MPI
3 human immunodeficiency virus infectious disease 31.3 IFNG IL10 TNF
4 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 31.3 IFNG IL10 IL4
5 trypanosomiasis 31.2 IFNG IL10 IL1B IL4 TLR2 TNF
6 chagas disease 31.2 IFNG IL10 IL1B NOS2 TLR2 TLR4
7 arthritis 31.0 HLA-DRB1 IFNG IL10 IL1A IL1B TNF
8 leprosy 3 30.8 IFNG IL10 SLC11A1 TLR2 TNF
9 conjunctivitis 30.8 IFNG IL13 IL4 IL5
10 dermatitis 30.7 IFNG IL13 IL4 IL5
11 acquired immunodeficiency syndrome 30.7 IFNG IL10 IL1B RN7SL1 TNF
12 strongyloidiasis 30.6 IFNG IL13 IL5
13 lepromatous leprosy 30.6 IFNG IFNGR1 IL10 TLR2 TNF
14 hematopoietic stem cell transplantation 30.6 IFNG IL10 TNF
15 pulmonary tuberculosis 30.5 HLA-DRB1 IFNG IFNGR1 IL10 IL4 SLC11A1
16 pericarditis 30.5 IFNG IL1B TNF
17 filariasis 30.5 IFNG IL10 IL5 TLR2 TLR4 TNF
18 rheumatoid arthritis 30.5 HLA-DRB1 IFNG IL10 IL1A IL1B IL4
19 systemic lupus erythematosus 30.5 HLA-DRB1 IFNG IL10 IL1B IL4 ITGAM
20 cytokine deficiency 30.5 IL13 IL5
21 toxoplasmosis 30.4 IFNG IL10 IL1B IL4 TLR2 TLR4
22 uveitis 30.4 IFNG IL10 IL1A IL4 TNF
23 meningitis 30.4 IFNG IL10 IL1B TLR2 TNF
24 bacterial infectious disease 30.4 IFNG IL10 IL1B ITGAM SLC11A1 TLR2
25 sezary's disease 30.4 IFNG IL4 IL5
26 hepatitis a 30.4 IFNG IL10 TNF
27 endocarditis 30.4 IL10 TLR2 TNF
28 melioidosis 30.4 IFNG IL10 TLR2 TLR4 TNF
29 panuveitis 30.3 HLA-DRB1 IL10 TNF
30 filarial elephantiasis 30.3 IL10 IL4 IL5 TLR2
31 fascioliasis 30.3 IFNG IL10 IL1B
32 prostatitis 30.3 IL10 IL1B TNF
33 keratitis, hereditary 30.3 IL1B TLR2 TLR4
34 psoriatic arthritis 30.3 HLA-DRB1 IL13 IL1A IL1B TNF
35 rheumatic disease 30.2 HLA-DRB1 IFNG IL10 IL1B TNF
36 schistosomiasis 30.2 IFNG IFNGR1 IL10 IL13 IL4 IL5
37 connective tissue disease 30.2 HLA-DRB1 IFNG IL10 IL1A TNF
38 orofacial granulomatosis 30.2 IFNG IL10 IL4 TNF
39 malaria 30.2 HLA-DRB1 IFNG IFNGR1 IL10 IL13 IL1A
40 coccidiosis 30.2 IFNG IL10 IL4 TNF
41 hemorrhagic fever 30.2 HLA-DRB1 IFNG IL10 TNF
42 folliculitis 30.2 IFNG IL4 IL5
43 bacterial sepsis 30.2 IL10 NOS2 TLR4 TNF
44 mixed connective tissue disease 30.1 HLA-DRB1 IFNG IL10 TNF
45 multiple sclerosis 30.1 HLA-DRB1 IFNG IL10 IL1B IL4 NOS2
46 aphthous stomatitis 30.1 IL10 IL1B IL4 TLR2 TNF
47 leptospirosis 30.1 IFNG IL10 IL1B TLR2 TNF
48 brucellosis 30.0 IFNG IL10 IL4 SLC11A1 TLR4 TNF
49 hypereosinophilic syndrome 30.0 IL13 IL4 IL5
50 tonsillitis 30.0 IFNG IL1A IL1B IL4 TNF

Graphical network of the top 20 diseases related to Leishmaniasis:



Diseases related to Leishmaniasis

Symptoms & Phenotypes for Leishmaniasis

Human phenotypes related to Leishmaniasis:

33 (show all 24)
# Description HPO Frequency HPO Source Accession
1 splenomegaly 33 hallmark (90%) HP:0001744
2 hepatomegaly 33 hallmark (90%) HP:0002240
3 pancytopenia 33 hallmark (90%) HP:0001876
4 abnormal bleeding 33 hallmark (90%) HP:0001892
5 skin ulcer 33 hallmark (90%) HP:0200042
6 papule 33 hallmark (90%) HP:0200034
7 lymphadenopathy 33 hallmark (90%) HP:0002716
8 skin plaque 33 hallmark (90%) HP:0200035
9 episodic fever 33 hallmark (90%) HP:0001954
10 rhinitis 33 hallmark (90%) HP:0012384
11 night sweats 33 hallmark (90%) HP:0030166
12 abnormal oral mucosa morphology 33 hallmark (90%) HP:0011830
13 abnormal macrophage morphology 33 hallmark (90%) HP:0004311
14 arthralgia 33 frequent (33%) HP:0002829
15 anemia 33 frequent (33%) HP:0001903
16 pallor 33 frequent (33%) HP:0000980
17 weight loss 33 frequent (33%) HP:0001824
18 increased antibody level in blood 33 frequent (33%) HP:0010702
19 hypoalbuminemia 33 frequent (33%) HP:0003073
20 elevated hepatic transaminase 33 frequent (33%) HP:0002910
21 fatigue 33 occasional (7.5%) HP:0012378
22 thrombocytopenia 33 occasional (7.5%) HP:0001873
23 anorexia 33 occasional (7.5%) HP:0002039
24 leukopenia 33 occasional (7.5%) HP:0001882

UMLS symptoms related to Leishmaniasis:


fever, pruritus, exanthema

GenomeRNAi Phenotypes related to Leishmaniasis according to GeneCards Suite gene sharing:

27 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.87 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.87 IL13
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.87 IL10 TLR4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.87 TLR4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.87 HLA-DRB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.87 IL10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.87 HLA-DRB1 IL10 IL13 TLR4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.87 IL13
9 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.87 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.87 HLA-DRB1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.87 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.87 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.87 HLA-DRB1 TLR4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.87 HLA-DRB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.87 HLA-DRB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.87 HLA-DRB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.87 IL10
18 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.87 IL13
19 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.87 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.87 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.87 TLR4
22 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.87 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.87 IL13
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.87 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.87 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.87 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.87 HLA-DRB1 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.87 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.87 IL10

MGI Mouse Phenotypes related to Leishmaniasis:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.32 IFNG IFNGR1 IL10 IL13 IL1A IL1B
2 immune system MP:0005387 10.28 IFNG IFNGR1 IL10 IL13 IL1A IL1B
3 homeostasis/metabolism MP:0005376 10.27 IFNG IFNGR1 IL10 IL13 IL1A IL1B
4 cellular MP:0005384 10.25 IFNG IFNGR1 IL10 IL13 IL4 ITGAM
5 digestive/alimentary MP:0005381 10.24 IFNG IFNGR1 IL10 IL13 IL4 IL5
6 cardiovascular system MP:0005385 10.22 IFNG IFNGR1 IL10 IL1A IL1B MPI
7 integument MP:0010771 10.14 IFNG IFNGR1 IL10 IL13 IL1A IL1B
8 neoplasm MP:0002006 10.06 IFNG IFNGR1 IL10 IL1A IL1B IL5
9 nervous system MP:0003631 10.03 IFNG IFNGR1 IL10 IL13 IL1B IL4
10 liver/biliary system MP:0005370 10.02 IFNG IFNGR1 IL10 IL4 IL5 NOS2
11 reproductive system MP:0005389 9.81 IFNG IFNGR1 IL10 IL13 IL4 IL5
12 respiratory system MP:0005388 9.61 IFNG IL10 IL13 IL4 IL5 NOS2
13 skeleton MP:0005390 9.36 IFNG IFNGR1 IL10 IL13 IL1B IL4

Drugs & Therapeutics for Leishmaniasis

Drugs for Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1397-89-3 14956 5280965
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Miltefosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
4
deoxycholic acid Approved Phase 4,Phase 3,Not Applicable 83-44-3 222528
5
Paromomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 1263-89-4, 7542-37-2 165580
6
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
7
Primaquine Approved Phase 4 90-34-6 4908
8
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
9
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
10
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
11
Nevirapine Approved Phase 4 129618-40-2 4463
12
meglumine antimoniate Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 133-51-7
13
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
14 Liposomal amphotericin B Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antimony Sodium Gluconate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Not Applicable
23 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
24 Analgesics Phase 4,Phase 2,Phase 3
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
26 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
27 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
28 Antiviral Agents Phase 4,Phase 3,Not Applicable
29 Cholagogues and Choleretics Phase 4,Phase 3,Not Applicable
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Not Applicable
31 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3,Not Applicable
32 Anesthetics Phase 4
33 Antimalarials Phase 4
34 Chloroquine diphosphate Phase 4 50-63-5
35 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
36 Cytochrome P-450 CYP3A Inhibitors Phase 4
37 HIV Protease Inhibitors Phase 4,Phase 3
38 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
39
protease inhibitors Phase 4,Phase 3
40 Anti-Retroviral Agents Phase 4,Phase 3
41 Reverse Transcriptase Inhibitors Phase 4
42 Nucleic Acid Synthesis Inhibitors Phase 4
43 Cytochrome P-450 CYP3A Inducers Phase 4
44 Anti-HIV Agents Phase 4,Phase 3
45 Atazanavir Sulfate Phase 4
46
Pentamidine Approved, Investigational Phase 3,Phase 2 100-33-4 4735
47
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
48
Ethanol Approved Phase 2, Phase 3 64-17-5 702
49
Salicylic acid Approved, Investigational, Vet_approved Phase 2, Phase 3 69-72-7 338
50
Pentoxifylline Approved, Investigational Phase 2, Phase 3,Phase 3 6493-05-6 4740

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Unknown status NCT01566552 Phase 4 AMBISOME
2 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
3 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
4 Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
5 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Completed NCT00818818 Phase 4 Meglumine antimoniate
6 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
7 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
8 Pharmacokinetics of Miltefosine in Children and Adults Completed NCT01462500 Phase 4 Miltefosine
9 Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh Completed NCT03311607 Phase 4 AmBisome
10 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Completed NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
11 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
12 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
13 Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
14 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Unknown status NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
15 Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Unknown status NCT02151630 Phase 2, Phase 3 Pyruvic acid;Salicylic Acid
16 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
17 Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
18 Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
19 Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
20 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
21 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
22 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
23 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
24 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Completed NCT01360762 Phase 3 Pentamidine
25 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
26 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
27 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
28 Combination Therapy in Indian Visceral Leishmaniasis Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
29 Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis Completed NCT00257530 Phase 3 Imiquimod
30 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
31 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
32 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3 Miltefose
33 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) Completed NCT01644682 Phase 3
34 Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
35 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
36 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Completed NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
37 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
38 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
39 Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
40 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
41 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
42 Nicotinamide in the Treatment of Psoriasis Completed NCT01763424 Phase 2, Phase 3 Calcipotriol plus Nicotinamide;Calcipotriol
43 Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Completed NCT01348308 Phase 3 Maraviroc (Celsentri);Placebo
44 Low Antimonial Dosage in American Mucosal Leishmaniasis Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
45 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
46 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3 Miltefosine
47 Miltefosine and GM-CSF in Cutaneous Leishmaniasis Not yet recruiting NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
48 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Not yet recruiting NCT03829917 Phase 2, Phase 3 Miltefosine and Paromomycin;miltefosine;paromomycin
49 High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
50 Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®

Search NIH Clinical Center for Leishmaniasis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: leishmaniasis

Genetic Tests for Leishmaniasis

Anatomical Context for Leishmaniasis

MalaCards organs/tissues related to Leishmaniasis:

42
Testes, Skin, T Cells, Liver, Spleen, Bone, Bone Marrow

Publications for Leishmaniasis

Articles related to Leishmaniasis:

(show top 50) (show all 7467)
# Title Authors Year
1
Tissue and Blood Protozoa including Toxoplasmosis, Chagas disease, Leishmaniasis, Babesia, Acanthamoeba, Balamuthia, & Naegleria in Solid Organ Transplant Recipients - Guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation. ( 30900295 )
2019
2
The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice. ( 30898544 )
2019
3
Expansion of urban cutaneous leishmaniasis into rural areas of southeastern Iran: Clinical, epidemiological and phylogenetic profiles explored using 7SL high resolution melting-PCR analysis. ( 30912874 )
2019
4
Gene expression profile of cytokines produced in biopsies from patients with American cutaneous leishmaniasis. ( 30273562 )
2019
5
Fractional Ablative CO2 Laser Followed by Topical Application of Sodium Stibogluconate for Treatment of Active Cutaneous Leishmaniasis: A Randomized Controlled Trial. ( 30281141 )
2019
6
Case Reports: Late Emergence of Cutaneous Leishmaniasis in an Immunocompromised Patient in a Non-Endemic Setting. ( 30520412 )
2019
7
Presence of parasite DNA in clinically unaffected nasal mucosa during cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. ( 30616010 )
2019
8
Evaluation of point of care tests for the diagnosis of cutaneous leishmaniasis in Suriname. ( 30616544 )
2019
9
Microneedle-Based Delivery of Amphotericin B for Treatment of Cutaneous Leishmaniasis. ( 30617619 )
2019
10
Endemic Human Cutaneous Leishmaniasis Incidence in the United States-Reply. ( 30624559 )
2019
11
Endemic Human Cutaneous Leishmaniasis Incidence in the United States. ( 30624563 )
2019
12
Eligibility for Local Therapies in Adolescents and Adults with Cutaneous Leishmaniasis from Southwestern Colombia: A Cross-Sectional Study. ( 30628567 )
2019
13
Autochthonous cutaneous leishmaniasis in urban domestic animals (Felis catus / Canis lupus familiaris) from central-western Venezuela. ( 30633896 )
2019
14
Assessment of intralesional cytokine profile of cutaneous leishmaniasis caused by Leishmania donovani in Sri Lanka. ( 30642262 )
2019
15
Label-free quantitative proteomic analysis reveals potential biomarkers for early healing in cutaneous leishmaniasis. ( 30648003 )
2019
16
Anti-TNF-associated cutaneous leishmaniasis: a single-institution experience. ( 30659588 )
2019
17
Resolution of Cutaneous Leishmaniasis and Persistence of Leishmania major in the Absence of Arginase 1. ( 30665936 )
2019
18
How cutaneous leishmaniasis and treatment impacts in the patients' lives: A cross-sectional study. ( 30682151 )
2019
19
The increasead of neglected cutaneous leishmaniasis in Gaziantep province of Turkey after mass human migration. ( 30710533 )
2019
20
Cutaneous Leishmaniasis: Updates in Diagnosis and Management. ( 30712756 )
2019
21
Isolated conjunctival involvement in a case of cutaneous leishmaniasis. ( 30722746 )
2019
22
Detection, genotyping, and phylogenetic analysis of Leishmania isolates collected from infected Jordanian residents and Syrian refugees who suffered from cutaneous leishmaniasis. ( 30729301 )
2019
23
Intralesional sodium stibogluconate under inhaled anesthesia for the treatment of cutaneous leishmaniasis in children: A retrospective cohort. ( 30731176 )
2019
24
Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis. ( 30738195 )
2019
25
Host's immune response in unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis treated by meglumine antimoniate: A case-control study of Th1 and Th2 pathways. ( 30771740 )
2019
26
Rhinophyma-Like Cutaneous Leishmaniasis due to Leishmania aethiopica Treated Successfully with Liposomal Amphotericin B. ( 30774067 )
2019
27
Chitosan-based biocompatible dressing for treatment of recalcitrant lesions of cutaneous leishmaniasis: A pilot clinical study. ( 30785121 )
2019
28
Leishmania spp. Infection Rate and Feeding Patterns of Sand Flies (Diptera: Psychodidae) from a Hyperendemic Cutaneous Leishmaniasis Community in Panamá. ( 30793681 )
2019
29
Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates. ( 30802261 )
2019
30
Thirty years of cutaneous leishmaniasis in Tadla-Azilal focus, Morocco. ( 30805563 )
2019
31
Histological and immunological differences between zoonotic cutaneous leishmaniasis due to Leishmania major and sporadic cutaneous leishmaniasis due to Leishmania infantum. ( 30810524 )
2019
32
Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis. ( 30815688 )
2019
33
Diel periodicity and visual cues guide oviposition behavior in Phlebotomus papatasi, vector of old-world cutaneous leishmaniasis. ( 30835733 )
2019
34
Disseminated Cutaneous Leishmaniasis in a Patient Infected by Leishmania panamensis. ( 30843505 )
2019
35
Host and parasite responses in human diffuse cutaneous leishmaniasis caused by L. amazonensis. ( 30845223 )
2019
36
Imported cutaneous leishmaniasis: a 13-year experience of a Polish tertiary center. ( 30858788 )
2019
37
Alterations in monocyte subsets and cytokine production after TLR activation in American Cutaneous Leishmaniasis. ( 30870579 )
2019
38
Performance of immunohistochemistry as a useful tool for the diagnosis of cutaneous leishmaniasis in Panama, Central America. ( 30885795 )
2019
39
10-Year Trends in Epidemiology, Diagnosis, and Treatment of Cutaneous Leishmaniasis in Hamadan Province, West of Iran (2007-2016). ( 30891438 )
2019
40
Randomized, double-blind study on intralesional metronidazole versus intralesional sodium stibogluconate in Leishmania donovani cutaneous leishmaniasis. ( 29764246 )
2019
41
Residual Efficacy of Insecticides Sprayed on Different Types of Surfaces Against Leishmaniasis and Filariasis Vectors in Egypt. ( 30753681 )
2019
42
Visceral Leishmaniasis and Glomerulonephritis: A Case Report. ( 30787856 )
2019
43
Association between Insulin-Like Growth Factor-I Levels and the Disease Progression and Anemia in Visceral Leishmaniasis. ( 30761980 )
2019
44
Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report. ( 30652793 )
2019
45
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. ( 30653490 )
2019
46
Unusual manifestations of visceral leishmaniasis in children: a case series and its spatial dispersion in the western region of São Paulo state, Brazil. ( 30658589 )
2019
47
Accuracy of a TaqMan-based real-time polymerase chain reaction combined to a Novy-MacNeal-Nicolle medium culture for the diagnosis of American tegumentary leishmaniasis. ( 30659669 )
2019
48
Eliminating visceral leishmaniasis in South Asia: the road ahead. ( 30670453 )
2019
49
Visceral Leishmaniasis. ( 30673546 )
2019
50
Comorbid infections induce progression of visceral leishmaniasis. ( 30674329 )
2019

Variations for Leishmaniasis

Expression for Leishmaniasis

Search GEO for disease gene expression data for Leishmaniasis.

Pathways for Leishmaniasis

Pathways related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.15 HLA-DRB1 IFNG IFNGR1 IL10 IL13 IL1A
2
Show member pathways
13.79 IFNG IFNGR1 IL10 IL13 IL1A IL1B
3
Show member pathways
13.66 IFNG IFNGR1 IL10 IL13 IL1A IL1B
4
Show member pathways
13.54 IL10 IL13 IL1A IL1B IL4 IL5
5
Show member pathways
13.5 HLA-DRB1 IFNG IFNGR1 IL10 IL13 IL1A
6
Show member pathways
13.36 IL10 IL13 IL1A IL1B IL4 IL5
7
Show member pathways
13.35 HLA-DRB1 IFNG IFNGR1 IL1A IL1B IL4
8
Show member pathways
13.33 IFNG IFNGR1 IL10 IL1B NOS2 TLR2
9
Show member pathways
13.04 HLA-DRB1 IFNG IFNGR1 IL10 IL13 IL1A
10 12.93 IFNG IFNGR1 IL13 IL4 IL5 NOS2
11
Show member pathways
12.77 IL1A IL1B TLR2 TLR4 TNF
12
Show member pathways
12.76 HLA-DRB1 IFNG IFNGR1 IL10 IL4 TNF
13
Show member pathways
12.75 IFNG IFNGR1 IL1A IL1B TNF
14
Show member pathways
12.74 HLA-DRB1 IFNG IFNGR1 IL13 IL1A IL1B
15 12.7 IFNG IL10 IL1B IL4 TLR2 TNF
16
Show member pathways
12.68 IL1A IL1B TLR2 TLR4 TNF
17
Show member pathways
12.67 IFNG IL10 IL1B NOS2 TNF
18
Show member pathways
12.61 IFNG IL10 IL1A IL1B IL4 IL5
19
Show member pathways
12.57 HLA-DRB1 IFNG IFNGR1 IL10 IL13 IL1A
20
Show member pathways
12.55 IFNG IFNGR1 IL10 IL13 IL4 IL5
21
Show member pathways
12.52 IFNG IL13 IL1B IL4 IL5 TLR2
22
Show member pathways
12.5 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
23
Show member pathways
12.48 IL13 IL1A IL1B IL5
24
Show member pathways
12.44 IFNG IL10 IL13 IL1A IL1B IL4
25
Show member pathways
12.4 IFNG IFNGR1 IL1A IL1B TLR4 TNF
26
Show member pathways
12.39 IFNG IL1B IL4 TNF
27 12.37 IFNG IFNGR1 NOS2 TLR2 TLR4 TNF
28
Show member pathways
12.36 IL1A IL1B NOS2 TLR2 TNF
29
Show member pathways
12.34 IFNG IFNGR1 IL1B IL4 NOS2 TLR2
30
Show member pathways
12.33 IL1A TLR2 TLR4 TNF
31 12.33 IL10 IL13 IL1A IL1B TNF
32
Show member pathways
12.25 IFNG IFNGR1 IL10 IL13 IL1A IL1B
33
Show member pathways
12.25 IFNG IFNGR1 IL10 IL1B TLR2 TLR4
34
Show member pathways
12.23 IL13 IL1A IL1B IL5 TLR2 TLR4
35 12.22 HLA-DRB1 ITGAM TLR2 TLR4
36 12.21 IFNG IFNGR1 IL1A IL1B TNF
37 12.21 IFNG IL1A IL1B IL4 NOS2 TLR4
38
Show member pathways
12.21 HLA-DRB1 IFNG IFNGR1 IL10 IL1A IL1B
39 12.19 IFNG IL10 IL4 IL5 ITGAM TNF
40 12.18 IFNG IL1A IL1B TNF
41
Show member pathways
12.16 IFNG IL13 IL1B IL4 ITGAM TLR2
42
Show member pathways
12.15 HLA-DRB1 IFNG IL1B IL4 NOS2
43 12.09 IL10 IL13 IL1A IL1B IL4 ITGAM
44 12.08 HLA-DRB1 IL1A IL1B IL4 IL5 ITGAM
45 12.04 HLA-DRB1 IFNG IL1A IL1B TLR2 TLR4
46 12.03 IFNG IFNGR1 NOS2 TLR4
47 12.03 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
48 11.95 IFNG IL10 IL1B ITGAM TNF
49 11.95 IFNG IL10 IL1B ITGAM NOS2 TLR2
50 11.95 HLA-DRB1 IFNG IFNGR1 IL10 IL1A IL1B

GO Terms for Leishmaniasis

Cellular components related to Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.35 HLA-DRB1 IL13 ITGAM TLR4 TNF
2 extracellular space GO:0005615 9.28 IFNG IL10 IL13 IL1A IL1B IL4

Biological processes related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 IL1B TLR2 TLR4 TNF
2 cellular response to lipopolysaccharide GO:0071222 9.97 IL10 IL1B NOS2 TLR4 TNF
3 regulation of signaling receptor activity GO:0010469 9.97 IFNG IL10 IL13 IL1A IL1B IL4
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 IL10 IL1B IL5 TNF
5 defense response to Gram-negative bacterium GO:0050829 9.91 NOS2 SLC11A1 TLR4
6 positive regulation of gene expression GO:0010628 9.91 IFNG IL13 IL1A IL1B IL4 SLC11A1
7 positive regulation of JNK cascade GO:0046330 9.9 IL1B TLR4 TNF
8 cellular response to mechanical stimulus GO:0071260 9.9 IL13 IL1B TLR4
9 positive regulation of inflammatory response GO:0050729 9.9 TLR2 TLR4 TNF
10 interferon-gamma-mediated signaling pathway GO:0060333 9.89 HLA-DRB1 IFNG IFNGR1
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 IFNG IL13 IL4
12 regulation of insulin secretion GO:0050796 9.88 IFNG IL1B NOS2 TNF
13 response to lipopolysaccharide GO:0032496 9.87 IL10 IL13 IL1B NOS2 SLC11A1 TLR2
14 positive regulation of interleukin-6 production GO:0032755 9.86 IL1B TLR2 TLR4 TNF
15 positive regulation of phagocytosis GO:0050766 9.85 IL1B SLC11A1 TNF
16 negative regulation of endothelial cell apoptotic process GO:2000352 9.85 IL10 IL13 IL4
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 IL1B TLR2 TLR4 TNF
18 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.84 IL1A IL1B TNF
19 positive regulation of interferon-gamma production GO:0032729 9.84 IL1B SLC11A1 TLR4 TNF
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.83 IFNG IL1B TLR4 TNF
21 negative regulation of interferon-gamma production GO:0032689 9.82 HLA-DRB1 IL10 TLR4
22 negative regulation of interleukin-6 production GO:0032715 9.82 IL10 TLR4 TNF
23 positive regulation of cytokine secretion GO:0050715 9.81 IL10 IL1A TNF
24 positive regulation of B cell proliferation GO:0030890 9.81 IL13 IL4 IL5 TLR4
25 inflammatory response GO:0006954 9.81 IL10 IL13 IL1A IL1B IL5 SLC11A1
26 positive regulation of interleukin-12 production GO:0032735 9.79 IFNG TLR2 TLR4
27 positive regulation of chemokine production GO:0032722 9.78 TLR2 TLR4 TNF
28 lipopolysaccharide-mediated signaling pathway GO:0031663 9.78 IL1B TLR2 TLR4 TNF
29 positive regulation of macrophage activation GO:0043032 9.77 IL10 IL13 TLR4
30 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.77 IFNG IL1B TNF
31 positive regulation of interleukin-8 production GO:0032757 9.76 IL1B TLR2 TLR4 TNF
32 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.75 IL10 IL1B TNF
33 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.74 TLR2 TLR4
34 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.74 IL1A IL1B
35 regulation of cytokine secretion GO:0050707 9.74 TLR2 TLR4
36 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.74 IFNG IFNGR1
37 I-kappaB phosphorylation GO:0007252 9.73 TLR2 TLR4
38 negative regulation of interleukin-17 production GO:0032700 9.73 IFNG TLR4
39 positive regulation of podosome assembly GO:0071803 9.73 IL5 TNF
40 response to molecule of bacterial origin GO:0002237 9.73 IL10 TLR2
41 macrophage activation GO:0042116 9.73 SLC11A1 TLR4
42 cellular response to lipoteichoic acid GO:0071223 9.72 TLR2 TLR4
43 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.72 TLR4 TNF
44 T-helper 1 type immune response GO:0042088 9.72 HLA-DRB1 TLR4
45 response to glucocorticoid GO:0051384 9.71 IL10 TNF
46 endothelial cell apoptotic process GO:0072577 9.71 IL10 TNF
47 positive regulation of chemokine biosynthetic process GO:0045080 9.71 IL1B TNF
48 microglial cell activation GO:0001774 9.71 IL13 ITGAM TLR2 TNF
49 ectopic germ cell programmed cell death GO:0035234 9.7 IL1A IL1B
50 regulation of establishment of endothelial barrier GO:1903140 9.7 IL1B TNF

Molecular functions related to Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 IFNG IL10 IL13 IL1A IL1B IL4
2 interleukin-1 receptor binding GO:0005149 9.16 IL1A IL1B
3 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4

Sources for Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....